Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mereo BioPharma Group plc MREO
$1.17
-$0.03 (-2.50%)
На 18:01, 12 мая 2023
+241.88%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
159079583.00000000
-
week52high
1.85
-
week52low
0.30
-
Revenue
1507000
-
P/E TTM
-3
-
Beta
0.79492900
-
EPS
-0.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
28 мар 2023 г. в 20:01
Описание компании
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 12 авг 2022 г. | |
| Needham | Buy | Buy | 06 июн 2022 г. |
| BTIG | Buy | 05 мая 2021 г. | |
| Needham | Buy | 05 апр 2021 г. | |
| SVB Leerink | Outperform | Outperform | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now?
Zacks Investment Research
21 апр 2023 г. в 13:43
Does MEREO BIOPHARMA (MREO) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 Hot Penny Stocks To Watch With News This Week
PennyStocks
21 мар 2023 г. в 09:01
Penny stocks to watch this week. The post 4 Hot Penny Stocks To Watch With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
15 ноя 2022 г. в 11:19
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Seeking Alpha
22 сент 2022 г. в 13:45
This is an update on the previously written report on Mereo BioPharma Group, a London-based clinical-stage biopharma. Frustrated with the lack of engagement from the management, the activist filled a request for a special shareholder meeting aiming to replace 4 incumbent directors.
How to Find Penny Stocks to Buy in Summer 2022
PennyStocks
16 июл 2022 г. в 11:30
Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.